In a recent analysis, Bank of America's Jason Gerberry has adjusted his rating on United Therapeutics (UTHR, Financial), elevating it from Underperform to Neutral while maintaining a price target of $314. This change comes after a noticeable decline in the stock's value, which has approached what is considered a floor valuation.
Gerberry suggests that the challenges faced by United Therapeutics in its core cardiopulmonary market are now fully accounted for in its current stock valuation. The analyst's reassessment indicates that the previous competitive pressures impacting the company's performance have already been factored into the stock's price, implying a stabilization in its future outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for United Therapeutics Corp (UTHR, Financial) is $398.38 with a high estimate of $600.00 and a low estimate of $314.00. The average target implies an upside of 39.92% from the current price of $284.73. More detailed estimate data can be found on the United Therapeutics Corp (UTHR) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, United Therapeutics Corp's (UTHR, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for United Therapeutics Corp (UTHR, Financial) in one year is $380.85, suggesting a upside of 33.76% from the current price of $284.73. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the United Therapeutics Corp (UTHR) Summary page.
